Pyxis Oncology 株価情報 (NASDAQ: PYXS)

最新ニュース Pyxis Oncology (NASDAQ:PYXS) 株価情報

PYXIS ONCOLOGY INC

Pyxis Oncology

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

Pyxis Oncology Inc

<p>The Company had a low operating cash outflow of $9.7 million including combined interest income and revenues of $8.8 million for the quarter. Trump Media incurred $10.9 million in legal fees, including costs related to the Company's March 2024 merger with a special purpose acquisition company—one of the longest SPAC mergers in history. The fees include those incurred in litigation aiming to recoup merger-related damages from those individuals and entities that the Company alleges caused the delay of the SPAC through their wrongful acts, as well as expenses related to the Company's reincorporation from Delaware to Florida.&nbsp;Additionally, Trump Media had net losses including $19.6 million in non-cash expenses for stock-based compensation, depreciation and amortization, resulting in a GAAP net loss of $31.7 million and a GAAP operating loss of $39.5 million.</p>
<p>In the first quarter, the Company continued to focus on building out its ecosystem, improving its existing platforms, and diversifying into financial services. Trump Media believes its robust and uncancellable infrastructure, expanding range of services, and strong balance sheet that includes $759.0 million of cash and investments strongly positions the Company to begin implementing monetization plans on its platforms, fully launch Truth.Fi financial products, and continue pursuing new assets and/or partnerships, including via potential mergers and acquisitions.</p>


Earnings

News

Trump Media Reports Q1 2025 Results; Says Ended Q1 With $759M In Cash/Investments; Operations Consumed $9.7M Of Cash Despite $10.9M In Primarily Legacy Legal Fees; Preparing To Launch Truth+ Subscription Service; Eyeing Further Expansion Through Mergers/Acquisitions; Revenues Of $8.8M

<p>UBS  analyst Mark Carden   maintains US Foods Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>) with a Buy and raises the price target from $83 to $84.</p>


Price Target

Analyst Ratings

USFD

UBS Maintains Buy on US Foods Hldg, Raises Price Target to $84

<p><a href="https://www.youtube.com/watch?v=E8UWKdm4tVQ">https://www.youtube.com/watch?v=E8UWKdm4tVQ</a></p>


Politics

Economics

General

President Trump Says Baseline Of 10% Tariffs; Says Some Will Be Higher; Says Could Be Excemptions; Says We Have To Make A Great Deal With China; Says He Had Given A Number To Bessent On How Low He Is Willing To Go On Tariffs

<p>UBS  analyst Taylor McGinnis   maintains BILL Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) with a Buy and raises the price target from $60 to $65.</p>


BILL

UBS Maintains Buy on BILL Holdings, Raises Price Target to $65

<p>UBS  analyst Gavin Parsons   maintains Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) with a Buy and raises the price target from $207 to $226.</p>


UBS Maintains Buy on Boeing, Raises Price Target to $226

<h3>Gainers</h3>
<ul>
<li><strong>Vince Holding</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) stock moved upwards by 17.6% to $1.94 during Friday's after-market session. The company's market cap stands at $24.4 million. </li>
<li><strong>ATA Creativity Global</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AACG#NASDAQ">AACG</a>) stock moved upwards by 8.98% to $0.97. The company's market cap stands at $30.5 million. </li>
<li><strong>Birks Group</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) stock rose 6.25% to $0.96. The market value of their outstanding shares is at $18.3 million. </li>
<li><strong>Dave &amp; Buster's Enter</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) stock increased by 5.68% to $20.99. The market value of their outstanding shares is at $724.4 million. </li>
<li><strong>United Homes Gr</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) shares moved upwards by 5.55% to $1.9. The market value of their outstanding shares is at $111.3 million. </li>
<li><strong>Jeffs Brands</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) shares rose 5.35% to $0.86. The company's market cap stands at $1.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>E-Home Household Service</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) stock decreased by 10.4% to $0.09 during Friday's after-market session. </li>
<li><strong>TCTM Kids IT Education</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSA#NASDAQ">VSA</a>) stock declined by 10.05% to $0.63. The market value of their outstanding shares is at $6.2 million. </li>
<li><strong>SharpLink Gaming</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) shares fell 7.83% to $3.3. The company's market cap stands at $1.8 million. </li>
<li><strong>Jiade</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) shares decreased by 5.61% to $0.5. The market value of their outstanding shares is at $12.2 million. </li>
<li><strong>Live Ventures</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIVE#NASDAQ">LIVE</a>) shares fell 4.66% to $19.46. The market value of their outstanding shares is at $60.4 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li><strong>INNEOVA Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INEO#NASDAQ">INEO</a>) shares decreased by 4.62% to $1.24. The market value of their outstanding shares is at $12.2 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Movers

AACG

INEO

JDZG

JFBR

LIVE

PLAY

SBET

VNCE

12 Consumer Discretionary Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Polyrizon</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock moved upwards by 57.1% to $0.58 during Friday's after-market session. The market value of their outstanding shares is at $3.9 million. </li>
<li><strong>NuCana</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares rose 17.35% to $0.05. </li>
<li><strong>Voyager Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) stock moved upwards by 13.56% to $3.6. The market value of their outstanding shares is at $199.2 million. The company's, Q1 earnings came out 3 days ago. </li>
<li><strong>Shuttle Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock moved upwards by 9.24% to $0.25. The market value of their outstanding shares is at $1.5 million. </li>
<li><strong>Gelteq</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) stock moved upwards by 8.75% to $1.49. The market value of their outstanding shares is at $14.0 million. </li>
<li><strong>CARISMA Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) stock increased by 8.08% to $0.21. The market value of their outstanding shares is at $8.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>SCWorx</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) stock declined by 12.9% to $0.53 during Friday's after-market session. The company's market cap stands at $1.2 million. </li>
<li><strong>Envoy Medical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock fell 8.88% to $1.54. The company's market cap stands at $32.8 million. </li>
<li><strong>Matinas BioPharma Hldgs</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) shares decreased by 6.39% to $0.66. The market value of their outstanding shares is at $3.3 million. </li>
<li><strong>CNS Pharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares declined by 6.2% to $1.06. The market value of their outstanding shares is at $3.1 million. </li>
<li><strong>Xencor</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) shares declined by 5.53% to $7.87. The market value of their outstanding shares is at $560.1 million. The company's, Q1 earnings came out 2 days ago. </li>
<li><strong>AquaBounty Techs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock fell 5.38% to $0.65. The company's market cap stands at $2.5 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CARM

CNSP

Envoy Medical, Inc. - Class A Common Stock

COCH

GELS

MTNB

NCNA

PLRZ

SHPH

VYGR

WORX

XNCR

12 Health Care Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Forward Air</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) stock increased by 11.2% to $18.14 during Friday's after-market session. The company's market cap stands at $551.8 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li><strong>C3is</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CISS#NASDAQ">CISS</a>) stock moved upwards by 9.3% to $4.11. The company's market cap stands at $2.9 million. </li>
<li><strong>Volato Group</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#AMEX">SOAR</a>) shares moved upwards by 8.73% to $2.48. The company's market cap stands at $4.5 million. </li>
<li><strong>PS International Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) shares moved upwards by 8.51% to $0.33. The market value of their outstanding shares is at $8.0 million. </li>
<li><strong>Aeries Technology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AERT#NASDAQ">AERT</a>) shares moved upwards by 7.31% to $0.75. The market value of their outstanding shares is at $33.4 million. </li>
<li><strong>LanzaTech Global</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) stock rose 6.12% to $0.23. The company's market cap stands at $45.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Vast Renewables</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) shares declined by 15.1% to $0.12 during Friday's after-market session. The market value of their outstanding shares is at $3.5 million. </li>
<li><strong>Solidion Technology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) stock decreased by 8.31% to $0.1. The market value of their outstanding shares is at $12.9 million. </li>
<li><strong>Click Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIK#NASDAQ">CLIK</a>) stock decreased by 7.13% to $0.23. The company's market cap stands at $7.3 million. </li>
<li><strong>Nuvve Holding</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) shares declined by 6.48% to $2.6. The company's market cap stands at $7.9 million. </li>
<li><strong>Momentus</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) shares fell 5.99% to $1.57. The company's market cap stands at $8.2 million. </li>
<li><strong>JE Cleantech Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCSE#NASDAQ">JCSE</a>) stock fell 5.19% to $1.28. The market value of their outstanding shares is at $6.7 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Advanced Environmental Recycling Technologies

AERT

CISS

CLIK

FWRD

JCSE

LNZA

MNTS

NVVE

PSIG

SOAR

VSTE

12 Industrials Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Next Technology Holding</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) stock moved upwards by 74.6% to $4.12 during Friday's after-market session. The market value of their outstanding shares is at $28.7 million. As per the press release, Q1 earnings came out today. </li>
<li><strong>Oblong</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) shares increased by 30.82% to $3.65. The company's market cap stands at $4.2 million. </li>
<li><strong>Wellchange Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) shares rose 7.87% to $0.29. The company's market cap stands at $13.3 million. </li>
<li><strong>Argo Blockchain</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) stock increased by 6.07% to $0.39. The company's market cap stands at $24.6 million. </li>
<li><strong>Lightwave Logic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWLG#NASDAQ">LWLG</a>) shares rose 4.95% to $1.06. The market value of their outstanding shares is at $132.0 million. </li>
<li><strong>SMX (Security Matters)</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) shares rose 4.6% to $1.59. The company's market cap stands at $4.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Abits Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) stock declined by 33.1% to $5.63 during Friday's after-market session. The market value of their outstanding shares is at $13.3 million. </li>
<li><strong>Infobird Co</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFBD#NASDAQ">IFBD</a>) shares fell 18.31% to $1.25. The company's market cap stands at $10.2 million. </li>
<li><strong>Research Frontiers</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFR#NASDAQ">REFR</a>) stock declined by 5.04% to $1.51. The company's market cap stands at $50.8 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li><strong>Pixelworks</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXLW#NASDAQ">PXLW</a>) shares decreased by 5.0% to $0.53. The market value of their outstanding shares is at $33.0 million. </li>
<li><strong>Mitek Systems</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MITK#NASDAQ">MITK</a>) stock fell 4.93% to $9.26. The company's market cap stands at $418.9 million. The company's, Q2 earnings came out yesterday. </li>
<li><strong>Ascent Solar Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTI#NASDAQ">ASTI</a>) shares fell 4.73% to $1.81. The market value of their outstanding shares is at $3.0 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ABTS

ARBK

ASTI

IFBD

LWLG

MITK

Next Technology Holding Inc. - Ordinary Shares

NXTT

OBLG

PXLW

REFR

12 Information Technology Stocks Moving In Friday's After-Market Session

<p>JP Morgan  analyst Christopher Horvers   maintains BJ's Wholesale Club Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) with a Neutral and raises the price target from $109 to $123.</p>


JP Morgan Maintains Neutral on BJ's Wholesale Club Hldgs, Raises Price Target to $123

Offerings

STWD

Starwood Property Trust Files For Mixed Shelf; Size Not Disclosed

Biotech

APLT

Applied Therapeutics To Present Full 12-Month Clinical Results From The INSPIRE Phase 3 Trial Of Govorestat In A Late-Breaking Abstract Selected For Oral Presentation At The Peripheral Nerve Society 2025 Annual Meeting, Being Held May 17-20, 2025 In Edinburgh, Scotland

<p>JP Morgan  analyst Rachel Vatnsdal   maintains 10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) with a Neutral and lowers the price target from $12 to $9.</p>


JP Morgan Maintains Neutral on 10x Genomics, Lowers Price Target to $9

<p><strong>Radiant Logistics</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RLGT#AMEX">RLGT</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Radiant Logistics will report an <strong>earnings per share</strong> (EPS) of $0.05. </p>
<p>Radiant Logistics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.12, leading to a 1.7% increase in the share price on the subsequent day.</p>
<p>Here's a look at Radiant Logistics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.10</td>
<td>0.14</td>
<td>0.10</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.22</td>
<td>0.16</td>
<td>0.14</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>-4.0%</td>
<td>3.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746824597_0.png" alt="eps graph" /></p>
<h3>Performance of Radiant Logistics Shares</h3>
<p>Shares of Radiant Logistics were trading at $6.03 as of May 08. Over the last 52-week period, shares are up 21.21%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/RLGT/earnings"><strong>To track all earnings releases for Radiant Logistics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


RLGT

Earnings Outlook For Radiant Logistics

<p>Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) will release its quarterly earnings report on Monday, 2025-05-12. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Xtant Medical Hldgs to report an <strong>earnings per share</strong> (EPS) of $-0.02.</p>
<p>Investors in Xtant Medical Hldgs are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $0.00, leading to a 4.39% drop in the share price on the subsequent day.</p>
<p>Here's a look at Xtant Medical Hldgs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.02</td>
<td>-0.02</td>
<td>-0.02</td>
<td>-0.01</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.02</td>
<td>-0.04</td>
<td>-0.03</td>
<td>-0.03</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>-13.0%</td>
<td>-5.0%</td>
<td>-12.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746824589_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Xtant Medical Hldgs were trading at $0.537 as of May 08. Over the last 52-week period, shares are down 36.92%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/XTNT/earnings"><strong>To track all earnings releases for Xtant Medical Hldgs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


XTNT

A Glimpse of Xtant Medical Hldgs's Earnings Potential

<p>JP Morgan  analyst Reginald Smith   maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Overweight and lowers the price target from $74 to $69.</p>


AFRM

JP Morgan Maintains Overweight on Affirm Holdings, Lowers Price Target to $69

<p>Pangaea Logistics Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANL#NASDAQ">PANL</a>) is gearing up to announce its quarterly earnings on Monday, 2025-05-12. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Pangaea Logistics Solns will report an <strong>earnings per share</strong> (EPS) of $-0.10.</p>
<p>Investors in Pangaea Logistics Solns are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $0.01, leading to a 12.19% increase in the share price on the subsequent day.</p>
<p>Here's a look at Pangaea Logistics Solns's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.17</td>
<td>0.27</td>
<td>0.15</td>
<td>0.09</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.16</td>
<td>0.24</td>
<td>0.10</td>
<td>0.14</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>12.0%</td>
<td>-7.000000000000001%</td>
<td>-1.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746824581_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Pangaea Logistics Solns were trading at $4.07 as of May 08. Over the last 52-week period, shares are down 48.52%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/PANL/earnings"><strong>To track all earnings releases for Pangaea Logistics Solns visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


PANL

Pangaea Logistics Solns's Earnings: A Preview

<p><strong>Century Casinos</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTY#NASDAQ">CNTY</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Century Casinos will report an <strong>earnings per share</strong> (EPS) of $-0.45. </p>
<p>Investors in Century Casinos are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS missed by $0.20 in the last quarter, leading to a 0.52% drop in the share price on the following day.</p>
<p>Here's a look at Century Casinos's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.49</td>
<td>-0.24</td>
<td>-0.28</td>
<td>-0.42</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.69</td>
<td>-0.26</td>
<td>-1.36</td>
<td>-0.45</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>7.000000000000001%</td>
<td>-0.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746824560_0.png" alt="eps graph" /></p>
<h3>Market Performance of Century Casinos's Stock</h3>
<p>Shares of Century Casinos were trading at $1.49 as of May 08. Over the last 52-week period, shares are down 48.1%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CNTY/earnings"><strong>To track all earnings releases for Century Casinos visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CNTY

Century Casinos's Earnings: A Preview

<p><strong>Imunon</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Imunon will report an <strong>earnings per share</strong> (EPS) of $-0.36. </p>
<p>Investors in Imunon are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS beat by $0.13 in the last quarter, leading to a 9.96% increase in the share price on the following day.</p>
<p>Here's a look at Imunon's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.36</td>
<td>-0.40</td>
<td>-0.60</td>
<td>-0.57</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.23</td>
<td>-0.34</td>
<td>-0.51</td>
<td>-0.52</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>10.0%</td>
<td>-3.0%</td>
<td>5.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746824551_0.png" alt="eps graph" /></p>
<h3>Market Performance of Imunon's Stock</h3>
<p>Shares of Imunon were trading at $0.835 as of May 08. Over the last 52-week period, shares are down 45.95%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/IMNN/earnings"><strong>To track all earnings releases for Imunon visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


IMNN

Imunon's Earnings: A Preview

<p>Quanterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>) will release its quarterly earnings report on Monday, 2025-05-12. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Quanterix to report an <strong>earnings per share</strong> (EPS) of $-0.69.</p>
<p>Quanterix bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company missed EPS by $0.08, which was followed by a 1.79% drop in the share price the next day.</p>
<p>Here's a look at Quanterix's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.22</td>
<td>-0.27</td>
<td>-0.26</td>
<td>-0.31</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.30</td>
<td></td>
<td>-0.25</td>
<td>-0.26</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>-18.0%</td>
<td>-15.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Market Performance of Quanterix's Stock</h3>
<p>Shares of Quanterix were trading at $5.51 as of May 08. Over the last 52-week period, shares are down 68.68%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analysts' Perspectives on Quanterix</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Quanterix.</p>
<p>A total of 3 analyst ratings have been received for Quanterix, with the consensus rating being Buy. The average one-year price target stands at $13.67, suggesting a potential 148.09% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of MaxCyte, Maravai LifeSciences and Rapid Micro Biosystems, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for MaxCyte, with an average 1-year price target of $9.0, suggesting a potential 63.34% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Maravai LifeSciences, with an average 1-year price target of $4.62, suggesting a potential 16.15% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Rapid Micro Biosystems, with an average 1-year price target of $8.0, suggesting a potential 45.19% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for MaxCyte, Maravai LifeSciences and Rapid Micro Biosystems, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quanterix</td>
<td>Buy</td>
<td>9.32%</td>
<td>$21.11M</td>
<td>-3.48%</td>
</tr>
<tr>
<td>MaxCyte</td>
<td>Buy</td>
<td>-44.51%</td>
<td>$6.41M</td>
<td>-5.05%</td>
</tr>
<tr>
<td>Maravai LifeSciences</td>
<td>Neutral</td>
<td>-23.92%</td>
<td>$18.96M</td>
<td>-7.80%</td>
</tr>
<tr>
<td>Rapid Micro Biosystems</td>
<td>Outperform</td>
<td>29.68%</td>
<td>$981K</td>
<td>-12.10%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Quanterix ranks highest in revenue growth among its peers. It also leads in gross profit margin. However, it has the lowest return on equity.</p>
<h3>Discovering Quanterix: A Closer Look</h3>
<p>Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs &amp; Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.</p>
<h3>Key Indicators: Quanterix's Financial Health</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Quanterix's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>9.32%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Quanterix's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-34.09%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-3.48%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Quanterix's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>-2.84%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.11</strong>, Quanterix adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/QTRX/earnings"><strong>To track all earnings releases for Quanterix visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


QTRX

Earnings Outlook For Quanterix

Press Releases

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

Health Care

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Comments

Pyxis Oncology

ニュース

最新ニュース Pyxis Oncology (NASDAQ:PYXS) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル